Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Mizuho Securities

Mizuho Cuts WEC Energy's Price Target By 13%

Mizuho Securities analyst Anthony Crowdell lowered the price target on WEC Energy Group Inc (NYSE:WEC) to $93 (an upside of 3%) from $107 while maintaining the Neutral rating on the shares. Mizuho hosted investor meetings with WEC’s Executive Chairman Gale Klappa and CFO Xia Liu. Crowdell says that the management highlighted the strong 6-7% EPS…

Read How Analysts Reacted To Devon Energy's RimRock Transaction

Mizuho Securities analyst Vincent Lovaglio raised the price target for Devon Energy Corp (NYSE:DVN) to $94 (an upside of 28%) from $92, reflecting the $865 million Rim Rock acquisition. The analyst states that the transaction adds 15kboed and 38k net acres to the company's existing 48kboed and 85k net acre Bakken position at ~4x free cash…

Mizuho Remains Bullish On This Small-Cap Stock's Migraine Candidate, But Why Did It Cut Price Target

Mizuho Remains Bullish On This Small-Cap Stock's Migraine Candidate, But Why Did It Cut Price Target

Mizuho Securities says that the Satsuma Pharmaceuticals Inc (NASDAQ: STSA) story is essentially unchanged. It remains bullish on STS101's potential as an effective, safe, and reliable intranasal dihydroergotamine (DHE) for migraine.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Rivian Is A 'Show-Me-The-Money' Story But Has 'More Pieces In Place' Than Peers: Analysts React To Q1 Earnings

Electric vehicle company Rivian Automotive Inc (NASDAQ: RIVN) reported first-quarter production of 2,553 vehicles. The company delivered 1,227 vehicles in the first quarter and reported more than 90,000 net pre-orders of its Rivian R1 electric pickup truck.

Analysts Say Acadia's Negative Pain Data Increases Focus On Pimavanserin For Alzheimer's-Related Psychosis

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) announced the primary endpoint miss of the phase 2 POC study of ACP-044 in acute postoperative pain following bunionectomy, a surgical procedure that moves toes back into the correct position. RBC Capital Markets writes that although trends of pain reduction were observed in the 400 mg QID ACP-044 arm compared…

Why This Analyst Believes Okta Stock Is 'Difficult To Ignore,' Noting An Increase In Cybersecurity Needs

Shares of Okta Inc (NASDAQ: OKTA) have lost 42% over the past six months, while the company’s organic growth remains strong, according to Mizuho Securities.

Mizuho Says This EV Company's Margins Are Ahead Of The Entire Industry

On CNBC, Mizuho Securities analyst Vijay Rakesh said growth stocks have seen some headwinds in the recent period due to the prospects of rate hikes by the Federal Reserve.

inkl

Read news from The Economist, FT, and more,
with one subscription

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Rivian Automotive Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play